Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222

We report the safety and immunogenicity results in participants administrated with a booster dose of protein subunit vaccine MVC-COV1901 at 12 (Group A) or 24 (Group B) weeks after two doses of AZD1222 (ChAdOx1 nCoV-19). The administration of the MVC-COV1901 vaccine as a booster dose in both groups...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Shu-Hsing, Lin, Yi-Chun, Chen, Cheng-Pin, Cheng, Chien-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609613/
https://www.ncbi.nlm.nih.gov/pubmed/36298566
http://dx.doi.org/10.3390/vaccines10101701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609613/
https://www.ncbi.nlm.nih.gov/pubmed/36298566
http://dx.doi.org/10.3390/vaccines10101701

Ejemplares similares